Henry Schein (HSIC) Raises FY2026 Guidance After Q3 Sales Reach $3.5B
Henry Schein (HSIC) reported Q3 sales of $3.5B, up 4.0% overall and 3.1% internally. GAAP EPS grew 26.2% and non-GAAP EPS grew 13.0% year over year. The company raised its FY2026 guidance but did not provide revised figures.
How this was made
The 30-second read
Why it matters
The guidance raise may attract growth‑oriented investors and could trigger short covering.
Market read
The earnings and guidance update is the primary catalyst for HSIC's near‑term price movement.
What to watch
Potential headwinds from supply chain constraints or regulatory changes could temper upside.
Background
Henry Schein is a leading distributor of health care products and services. The Q3 results show modest revenue growth and a notable EPS increase.
Ticker impact
Henry Schein reported Q3 sales of $3.5B and raised its FY2026 guidance, indicating improved earnings outlook.
upward pressure as investors price in higher earnings expectations
The company disclosed higher sales growth and EPS improvements, and explicitly raised its full‑year outlook, which typically leads to a positive market reaction.
Market effects
Positive for dental and medical supply distributors as the earnings beat may signal sector strength.
U.S. healthcare distribution market may see modest uplift.
Limited; primarily impacts U.S. investors and sector peers.
Counterpoint
If the guidance raise is modest and lacks specific targets, the market may already have priced it in.
Key entities
- companyHenry Schein Inc.
U.S. listed distributor of health‑care products (ticker HSIC).
